Both firms will co-promote FibroScan and LIVErHEALTHY as the preferred non-invasive testing and digital therapeutic platform, respectively, for NASH and NAFLD
Echosens and ChronWell partner to offer the latter’s LIVErHEALTHY platform in conjunction with FibroScan. (Credit: VSRao from Pixabay)
Echosens North America has entered into a partnership with digital health and therapeutics firm ChronWell to offer the latter’s LIVErHEALTHY platform in conjunction with its FibroScan non-invasive solution.
Under the terms of the agreement, the US-based medical technology company and ChronWell will also increase digital collaboration between their platforms.
Both firms will also co-promote FibroScan and LIVErHEALTHY as the preferred non-invasive testing and digital therapeutic platform, respectively, for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
ChronWell CEO Joe Rubinsztain said: “NAFLD and NASH remain a silent and dangerous epidemic for over 80 million Americans.
“We are proud to partner with Echosens to offer healthcare providers and payers a scalable and cost-effective way to identify and treat those suffering from this alarming condition.”
LIVErHEALTHY is a digital health platform that targets metabolic conditions such as NAFLD and NASH. The platform is said to help providers in delivering care interventions based on published medical guidelines with the help of software programmes.
FibroScan, on the other hand, is a portfolio of solutions, designed for the assessment and management of patients with chronic liver diseases. It produces biomarkers for assessing and monitoring patients over time and uses uniform algorithms that are said to minimise inter-operator variability and remove inter-system variability.
Echosens North America CEO Jon Gingrich said: “This strategic partnership is a powerful combination that reflects our collective commitment to ending the epidemic of fatty liver disease and halting the progression of NAFLD/NASH.
“LIVErHEALTHY complements our FibroScan platform, which includes solutions for hospitals, clinics, and private practices. Together, these important tools will support liver programs to ultimately improve patient outcomes.”